Article
Alpelisib enhances cisplatin mediated cytotoxicity in non-mutated, PIK3CA-dependent high-grade serous ovarian cancer.
Journal of ovarian research - 23 Jun 2026
Mehrotra Megha, Chakraborty Sourav, Saldanha Elveera, Joshi Diksha, Dhadve Ajit, Sakpal Asmita, Chandrani Pratik, Maheshwari Amita, Menon Santosh, Ghosh Jaya, Gupta Sudeep, Ray Pritha
Abstract excerpt
BACKGROUND: High-Grade Serous Ovarian Cancer (HGSOC) has a dismal five-year survival rate (< 30%) owing to late detection and recurrence caused by platinum resistance. Targeted therapy exhibits efficacy only within a limited patient population, warranting the need to identify new therapeutic regimes. Herein, we investigated the efficacy of a PIK3CA inhibitor, alpelisib, combined with cisplatin using malignant...
Read the complete abstract on PubMedTopics
- Female
- Humans
- Cisplatin
- Class I Phosphatidylinositol 3-Kinases
- Ovarian Neoplasms
